- Conditions
- Total Parenteral Nutrition-induced Cholestasis
- Interventions
- Omegaven®
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 4 Weeks to 18 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 29
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Parenteral Nutrition-related Hepatitis
- Interventions
- Omegaven
- Drug
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Cholestasis, Jaundice, Obstructive
- Interventions
- SMOFlipid
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 23 Weeks to 1 Year
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Cholestasis
- Interventions
- Omega-3 fish oil lipid emulsion
- Drug
- Lead sponsor
- Kapiolani Medical Center For Women & Children
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Cancer, Hepatic Injury
- Interventions
- Omegaven
- Drug
- Lead sponsor
- Midwestern Regional Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Zion, Illinois
- Conditions
- Hematopoietic Stem Cell Transplantation
- Interventions
- Omegaven, Soybean oil lipid emulsion
- Drug
- Lead sponsor
- Alexandra N. Carey
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Parenteral Nutrition Associated Liver Disease PNALD, Cholestasis
- Interventions
- Omegaven™
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Malnutrition, Child, Malnutrition, Essential Fatty Acid Deficiency (EFAD), Parenteral Nutrition Associated Cholestasis
- Interventions
- SMOFlipid® (lipid injectable emulsion)
- Drug
- Lead sponsor
- Fresenius Kabi
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 2 more
- Conditions
- Total Parenteral Nutrition-Induced Cholestasis
- Interventions
- Omegaven
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- Up to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Kidney Diseases
- Interventions
- Canola oil, Arginine, Fish oil emulsion
- Dietary Supplement
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 4 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2004
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Durham, North Carolina + 1 more
- Conditions
- Short Bowel Syndrome, Intestinal Fistula, Crohn Disease, Intestinal Obstruction
- Interventions
- SMOFLipid, Intralipid
- Dietary Supplement
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Cholestasis of Parenteral Nutrition
- Interventions
- Smoflipid 20% Lipid Emulsion for Injection, Intralipid, 20% Intravenous Emulsion
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- Not listed
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Total Parenteral Nutrition-induced Cholestasis, Cholestasis, Short Bowel Syndrome, Gastroschisis, Intestinal Atresia, Infant, Premature, Diseases, Cholestasis of Parenteral Nutrition
- Interventions
- Omegaven
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Home Parenteral Nutrition, Short Bowel Syndrome
- Interventions
- SMOFLipid, Standard therapy
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Retinopathy of Prematurity
- Interventions
- Omegaven, Standard lipids (primarily omega-6 fatty acids)
- Drug · Dietary Supplement
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- Up to 7 Days
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Parenteral Nutrition Associated Liver Disease, Short Bowel Syndrome, Gastrointestinal Disease
- Interventions
- Omegaven®
- Drug
- Lead sponsor
- Mark Puder
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cholestasis, Growth Failure
- Interventions
- SMOFlipid
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 14 Days to 1 Year
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Total Parenteral Nutrition-induced Cholestasis
- Interventions
- Omegaven®
- Drug
- Lead sponsor
- Jeffrey Rudolph
- Other
- Eligibility
- 2 Months to 10 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Cholestasis
- Interventions
- Omegaven
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 1 Month to 18 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Liver Disease
- Interventions
- Intravenous Lipid Emulsion Comprised of Fish Oil
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 14 Days to 24 Months
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Prematurity
- Interventions
- Intralipid, 20% Intravenous Emulsion, Soybean oil Medium-chain triglycerides Olive oil Fish Oil (SMOF) lipid
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 0 Days to 8 Days
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days
- Interventions
- Smoflipid 20% (investigational lipid for parenteral nutrition), Intralipid® 20%
- Drug
- Lead sponsor
- Fresenius Kabi
- Industry
- Eligibility
- 0 Weeks and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 13
- States / cities
- Palo Alto, California • San Diego, California • New Haven, Connecticut + 8 more
- Conditions
- Malnutrition, Child
- Interventions
- Smoflipid, Intralipid, 20%
- Drug
- Lead sponsor
- Fresenius Kabi
- Industry
- Eligibility
- 3 Months to 16 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Human Milk, Neonate, Breast Milk
- Interventions
- Targeted Fortification, The Miris Human Milk Analyzer
- Dietary Supplement · Device
- Lead sponsor
- MetroHealth Medical Center
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio